Phase Ib DART Trial Examines Combination Axitinib and Dalantercept

Interfering with two different stages of angiogenesis concurrently proves promising in clear cell renal cell carcinoma (RCC) based on early clinical results from the DART trial. In this phase Ib study of combined treatment with axitinib and dalantercept, objective responses have been observed in 25% of patients, along with a preliminary median progression-free survival duration of 8.3 months (Abstract 407).03/01/2015
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news